Safety profile of rosuvastatin: Results of a prescription-event monitoring study of 11 680 patients

Drug Safety

Volumn 30, Issue 2, 2007, Pages 157-170

  Kasliwal, Rachna ^a   Wilton, Lynda V ^a,b   Cornelius, Victoria ^a   Aurich Barrera, Beate ^a   Shakir, Saad A W ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ROSUVASTATIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; CHILD; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HALLUCINATION; HEADACHE; HEART PALPITATION; HEMATURIA; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; JAUNDICE; KIDNEY FAILURE; LABORATORY TEST; LASSITUDE; LIMB PAIN; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALAISE; MALE; MIGRAINE; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; MYOSITIS; NAUSEA; NEWBORN; PANCREATITIS; PHYSICIAN; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROTEINURIA; QUESTIONNAIRE; RHABDOMYOLYSIS; SIDE EFFECT; TREMOR; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENGLAND; FAMILY PRACTICE; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MUSCULAR DISEASES; PRESCRIPTIONS, DRUG; PRODUCT SURVEILLANCE, POSTMARKETING; PYRIMIDINES; QUESTIONNAIRES; RESEARCH DESIGN; SULFONAMIDES; TIME FACTORS;

EID: 33846704936     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730020-00005     Document Type: Article

References (32)

1. Murray C. Global burden of disease. Vol 1 of global burden of disease and injury series. Lopez A, editor. Boston: Harvard University School of Public Health, 1996
2. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110 (2): 227-39
3. Barter P, Kastelein J, Nunn A, et al. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 2003; 168 (2): 195-211
4. Lopez LM. Rosuvastatin: a high-potency HMG-CoA reductase inhibitor. J Am Pharm Assoc (Wash DC) 2005; 45 (4): 503-13
5. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systemic review and meta-analysis. BMJ 2003 Jun 28; 326 (7404): 1423
6. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000; 22 (6): 441-57
7. Weber W. Drug firm withdraws statin from the market. Lancet 2001; 358 (9281): 568
8. Health Canada. Warning. Updated safety information regarding Crestor. 2004 [online]. Available on URL: http://www.hcsc.gc.ca/english/protection/ warnings/2004/2004_34.htm [Accessed on 2005 May 5]
9. Medicines and Healthcare products Regulatory Agency. Drug Analysis Print. Data on suspected adverse drug reactions. Rosuvastatin [Accessed 2006 Apr 12]
10. Wolfe SM. Should rosuvastatin be withdrawn from the market? Lancet 2004; 364 (9445): 1578-9
11. AstraZeneca UK Limited. Summary of Product Characteristics for Crestor (rosuvastatin), 2005 Feb
12. Shakir SAW. PEM in the UK. Mann RD, Andrews EB, editors. Pharmacovigilance, 333-44. Chichester: John Wiley & Sons Ltd, 2002
13. ICH Harmonised Tripartite Guideline. Post-approval safety data management: definitions and standards for expedited reporting E2D. 2003
14. Shakir SAW. Causality and correlation in pharmacovigilance. In: Talbot J, Waller P, editors. Stephens' detection of new adverse drug reactions. 5th ed. Chichester: John Wiley & Sons Ltd, 2004: 43
15. Sample size considerations for pharmacoepidemiology studies. In: Strom BL, editor. Pharmacoepidemiology. 4th ed. Chichester: John Wiley & Sons Ltd, 2005: 36
16. Machin, D, Campbell M, Fayers P, et al. Chapter 7: post marketing surveillance. Table 7.1: sample sizes required to observe a single adverse reaction with a given probability and anticipated incidence. In: Machin D, editor. Sample size tables for clinical studies. 2nd ed. Oxford: Blackwell Science Ltd, 1997: 150
17. CIOMS. International Ethical Guidelines for Biomedical Research Involving Human Subjects. 2002. CIOMS
18. Royal College of Physicians of London. Guidelines on the practice of Ethical Committees in Medical Research involving Human Subjects. 1996
19. General Medical Council. Frequently asked questions supplement to: Confidentiality: protecting and providing information. 2004: 9
20. Key C, Layton D, Shakir SA. Results of a postal survey of the reasons for non-response by doctors in a Prescription Event Monitoring study of drug safety. Pharmacoepidemiol Drug Saf 2002; 11 (2): 143-8
21. Caballero J, Nahata M. Do statins slow down Alzheimer's disease? A review. J Clin Pharm Ther 2004; 29 (3): 209-13
22. Hargreaves IP, Heales S. Statins and myopathy. Lancet 2002; 359 (9307): 711-2
23. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292 (21): 2585-90
24. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002; 137 (7): 581-5
25. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998; 19 (1): 26-37
26. Pelli N, Setti M, Ceppa P, et al. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol 2003; 15 (8): 921-4
27. Hartleb M, Rymarczyk G, Januszewski K. Acute cholestatic hepatitis associated with pravastatin. Am J Gastroenterol 1999; 94 (5): 1388-90
28. Wolters LM, Van Buuren HR. Rosuvastatin-associated hepatitis with autoimmune features. Eur J Gastroenterol Hepatol 2005; 17 (5): 589-90
29. Shepherd J, Hunninghake DB, Stein EA, et al. Safety of rosuvastatin. Am J Cardiol 2004; 94 (7): 882-8
30. Davidson MH. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Opin Drug Saf 2004; 3 (6): 547-57
31. Singh S, Nautiyal A, Dolan JG. Recurrent acute pancreatitis possibly induced by atorvastatin and rosuvastatin. Is statin induced pancreatitis a class effect? JOP 2004; 5 (6): 502-4
32. Barry M. Rosuvastatin-warfarin drug interaction. Lancet 2004; 363 (9405): 328